The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19

Autor: Atmowihardjo, L, Schippers, JR, Bartelink, IH, Bet, PM, van Rein, N, Purdy, K, Cavalla, D, Comberiati, V, McElroy, A, Snape, SD, Bogaard, HJ, Heunks, L, Juffermans, N, Schultz, M, Tuinman, PR, Bos, LDJ, Aman, J

Publikováno v: Trials, 23(1):158. BioMed Central
Atmowihardjo, L, Schippers, J R, Bartelink, I H, Bet, P M, van Rein, N, Purdy, K, Cavalla, D, Comberiati, V, McElroy, A, Snape, S D, Bogaard, H J, Heunks, L, Juffermans, N, Schultz, M, Tuinman, P R, Bos, L D J & Aman, J 2022, ' The INVENT COVID trial : a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19 ', Trials, vol. 23, no. 1, 158 . https://doi.org/10.1186/s13063-022-06055-9
Trials

Background The coronavirus disease 2019 (COVID-19) pandemic has led to a disruptive increase in the number of intensive care unit (ICU) admissions with acute respiratory distress syndrome (ARDS). ARDS is a severe, life-threatening medical condition c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9ee7718225d5fd4777c416f9c3ee3c6
https://research.vumc.nl/en/publications/9996d36f-0469-4714-b737-064e40574a78